Generali Asset Management SPA SGR Sells 1,959 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• Generali Asset Management SPA SGR reduced its stake in IDEXX Laboratories, Inc. by 20.9%, selling 1,959 shares, and now holds 7,427 shares worth approximately $3.98 million.
• A number of large investors have increased their holdings in IDEXX Laboratories, with Harbour Investments Inc. boosting its position by 27.3% during the second quarter.
• IDEXX Laboratories has received mixed ratings from analysts, with Weiss Ratings reaffirming a "buy" rating while Wall Street Zen downgraded it to a "buy" from "strong-buy."

Generali Asset Management SPA SGR lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 20.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,427 shares of the company's stock after selling 1,959 shares during the quarter. Generali Asset Management SPA SGR's holdings in IDEXX Laboratories were worth $3,983,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Harbour Investments Inc. boosted its position in shares of IDEXX Laboratories by 27.3% during the 2nd quarter. Harbour Investments Inc. now owns 98 shares of the company's stock valued at $53,000 after acquiring an additional 21 shares during the last quarter. AEGON ASSET MANAGEMENT UK Plc boosted its position in shares of IDEXX Laboratories by 50.6% during the 2nd quarter. AEGON ASSET MANAGEMENT UK Plc now owns 48,308 shares of the company's stock valued at $25,887,000 after acquiring an additional 16,237 shares during the last quarter. Aries Wealth Management boosted its position in shares of IDEXX Laboratories by 2.5% during the 2nd quarter. Aries Wealth Management now owns 3,172 shares of the company's stock valued at $1,701,000 after acquiring an additional 76 shares during the last quarter. Sagespring Wealth Partners LLC boosted its position in shares of IDEXX Laboratories by 38.7% during the 2nd quarter. Sagespring Wealth Partners LLC now owns 756 shares of the company's stock valued at $406,000 after acquiring an additional 211 shares during the last quarter. Finally, Equitable Trust Co. boosted its position in shares of IDEXX Laboratories by 28.1% during the 2nd quarter. Equitable Trust Co. now owns 2,368 shares of the company's stock valued at $1,270,000 after acquiring an additional 519 shares during the last quarter. Institutional investors own 87.84% of the company's stock.

Analyst Ratings Changes

IDXX has been the subject of a number of recent research reports. Weiss Ratings restated a "buy (b-)" rating on shares of IDEXX Laboratories in a research report on Wednesday, October 8th. Wall Street Zen downgraded IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Sunday, September 28th. Jefferies Financial Group initiated coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 target price for the company. UBS Group initiated coverage on IDEXX Laboratories in a research report on Wednesday, October 1st. They issued a "neutral" rating and a $720.00 target price for the company. Finally, Piper Sandler restated a "neutral" rating and issued a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $656.50.

Insider Activity

In other news, EVP Michael Lane sold 8,411 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total transaction of $5,279,921.14. Following the transaction, the executive vice president directly owned 7,132 shares of the company's stock, valued at approximately $4,477,041.68. The trade was a 54.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 2,187 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total value of $1,415,710.71. Following the transaction, the director directly owned 262 shares in the company, valued at $169,600.46. This trade represents a 89.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,057 shares of company stock valued at $34,293,468. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $639.15 on Thursday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $688.12. The stock has a 50 day moving average price of $640.70 and a two-hundred day moving average price of $546.36. The company has a market capitalization of $51.13 billion, a P/E ratio of 53.22, a PEG ratio of 4.12 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion for the quarter, compared to analysts' expectations of $1.06 billion. During the same period in the previous year, the firm earned $2.44 earnings per share. The business's revenue was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.